PROTHENA CORP PUBLIC LTD CO

Previous wording

We may not generate the cash that is necessary to finance our operations in the foreseeable future. We incurred net income (losses) of($5.4) million for the six months ended June 30, 2024, and$(147.0) million and $(116.9) million, and$67.0 million for theyears ended December 31, 2023, 2022 and 2021, respectively. As of June 30, 2024, we had an accumulated deficit of$985.4 million. We expect to continue to incur substantial losses for the foreseeable future as we:

Current wording

We may not generate the cash that is necessary to finance our operations in the foreseeable future. We incurred net income (losses) of($64.4) million for the nine months ended September 30, 2024, and$(147.0) million and $(116.9) million, and$67.0 million for theyears ended December 31, 2023, 2022 and 2021, respectively. As of September 30, 2024, we had an accumulated deficit of$1.0 billion. We expect to continue to incur substantial losses for the foreseeable future as we:

Previous wording

As of June 30, 2024, we had cash and cash equivalents of$564.1 million. The majority of such cash is held in accounts at U.S. banking institutions that we believe are of high quality. Cash held in depository accounts may exceed the $250,000 Federal Deposit Insurance Corporation insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. Alth ough we believe, based on our current business plans, that our existing cash and cash equivalents will be sufficient to meet our obligations for at least the next twelve months, we anticipate that we will require additional capital in order to continue the research and development, and eventual commercialization, of our drug candidates. Our future capital requirements will depend on many factors that are currently unknown to us, including, without limitation:

Current wording

As of September 30, 2024, we had cash and cash equivalents of$519.3 million. The majority of such cash is held in accounts at U.S. banking institutions that we believe are of high quality. Cash held in depository accounts may exceed the $250,000 Federal Deposit Insurance Corporation insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. Alth ough we believe, based on our current business plans, that our existing cash and cash equivalents will be sufficient to meet our obligations for at least the next twelve months, we anticipate that we will require additional capital in order to continue the research and development, and eventual commercialization, of our drug candidates. Our future capital requirements will depend on many factors that are currently unknown to us, including, without limitation:

Previous wording

As with any publicly traded company, your percentage ownership in us may be diluted in the future because of equity issuances for acquisitions, capital raising transactions (including the sale of ordinary shares pursuant to our Amended Distribution Agreement, as may be further amended from time to time), or otherwise. We may need to raise additional capital in the future. If we are able to raise additional capital, we may issue equity or convertible debt instruments, which may severely dilute your ownership interest in us. In addition, we intend to continue to grant option awards to our directors, officers and employees, which would dilute your ownership stake in us. As of June 30, 2024, the number of ordinary shares available for issuance pursuant to outstanding and future equity awards under our equity planswas 15,387,311.

Current wording

As with any publicly traded company, your percentage ownership in us may be diluted in the future because of equity issuances for acquisitions, capital raising transactions (including the sale of ordinary shares pursuant to our Amended Distribution Agreement, as may be further amended from time to time), or otherwise. We may need to raise additional capital in the future. If we are able to raise additional capital, we may issue equity or convertible debt instruments, which may severely dilute your ownership interest in us. In addition, we intend to continue to grant option awards to our directors, officers and employees, which would dilute your ownership stake in us. As of September 30, 2024, the number of ordinary shares available for issuance pursuant to outstanding and future equity awards under our equity planswas 15,350,424.